Drug intelligence / Profile preview

danazol + sodium chloride

Development stage: Approved
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

This entry refers to a potential formulation containing danazol and sodium chloride. Danazol is a synthetic steroid with antigonadotropic and anti-estrogenic activities, used primarily for treating endometriosis, hereditary angioedema, and fibrocystic breast disease. It is typically available as oral capsules. Sodium chloride is common salt and is likely present as an excipient in a formulation, as there is no standard therapeutic combination product of danazol and sodium chloride described in the available information.

Targets

ER (Estrogen receptor)FSH (Follicle-stimulating hormone)AR (Adrenergic receptors)

Beyond the preview

Go deeper on danazol + sodium chloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on danazol + sodium chloride.

Explore the full profile